Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 8/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25693065 | 0.87 | HDAC3 (0.57) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL20132431 | 0.87 | HDAC3 (0.57) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL732445 | 0.83 | HDAC3 (0.47) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL22159239 | 0.82 | HDAC3 (0.51) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL63616 | 0.82 | HDAC3 (0.54) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL64453 | 0.81 | HRH3 (0.54) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL28314039 | 0.81 | HDAC3 (0.53) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| Lithium Ion SCHEMBL20163088 | 0.79 | HDAC3 (0.49) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| Ethylene SCHEMBL29031111 | 0.79 | HDAC3 (0.52) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL733377 | 0.78 | MEN1 (0.47) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023426-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | Critical Outcome Technologies, Inc. (CA) | 2016-05-25 | — | — | EP | disclosed |
| US-9284275-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| EP-2318406-B1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | CRITICAL OUTCOME TECHNOLOGIES INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| EP-2121681-B1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC (CA) | 2015-04-15 | — | — | EP | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-8034815-B2 | Imidazol-1-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanethione; Critical Outcome Technologies' Iead compound (COTI); kinase inhibitor; anticarcinogenic agent; especially small cell lung cancer; cervical, ovarian, skin, prostate, breast, colorectal, head, neck, or kidney cancer, sarcoma, leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| WO-2010006438-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | WO | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| WO-2008083491-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | SLC6A6, SLCO1B3, SLC5A1 | HDAC3 478/4885HDAC2 1318/4885CYP1A2 634/4885 |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | TBCA, SLC6A6, SLC5A1 | HDAC3 377/4885HDAC2 1160/4885CYP1A2 553/4885 |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | HDAC3 1121/4885HDAC2 274/4885CYP1A2 3990/4885 |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | HDAC3 1121/4885HDAC2 274/4885CYP1A2 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.